Publications by authors named "D Carballo"
Aims: The benefit of long-term beta-blocker therapy after acute coronary syndromes (ACS) without heart failure in the reperfusion era is uncertain. Two recent randomized trials found conflicting results. The present study assessed the safety of beta-blocker discontinuation within 12 months following ACS with LVEF ≥40%.
View Article and Find Full Text PDFArticle Synopsis
- The study assessed eligibility for marine omega-3 fatty acid eicosapentaenoic acid (EPA) supplementation in patients with acute coronary syndromes (ACS) in a Swiss cohort, as recommended by 2019 European Society of Cardiology guidelines.
- Out of 2643 patients, 32% were eligible for EPA supplementation one year post-ACS, with higher eligibility rates found in younger individuals, smokers, diabetics, hypertensive patients, and the obese.
- The research indicates that statins and other lipid-lowering therapies could reduce the percentage of these patients eligible for omega-3 supplementation, suggesting a need to address residual cardiovascular risk in those with hypertriglyceridemia.
Background: Long-term control of cardiovascular risk factors after acute coronary syndrome (ACS) is the cornerstone for preventing recurrence. We investigated the extent of cardiovascular risk factor management in males and females with and without familial hypercholesterolemia (FH) 5 years after ACS.
Methods: We studied patients hospitalized for ACS between 2009 and 2017 in a Swiss multicenter prospective cohort study.
Article Synopsis
- Desmoplakin cardiomyopathy is a recently defined heart condition causing left ventricular dysfunction, often leading to inflammation, fibrosis, and arrhythmias.
- A case study highlights a 46-year-old woman with this condition, who experienced multiple cardiac arrests due to a new variant in the desmoplakin gene and showed little improvement after receiving immunosuppressive treatment.
- The condition should be included in the evaluation of inflammatory heart diseases, and while some patients may benefit from immunosuppressive therapy, its effectiveness remains largely unknown.
Article Synopsis
- The study evaluated the effectiveness of a stepwise approach for treating cardiovascular risk factors based on European guidelines in patients with established atherosclerotic cardiovascular disease (ASCVD).
- Researchers analyzed data from two large patient cohorts, identifying treatment goals focused on lowering LDL cholesterol and blood pressure, as well as promoting smoking cessation and various medication combinations.
- Results indicated that using intensified Step 2 treatment options significantly reduces residual cardiovascular risk, improving patient outcomes and potentially decreasing events per 1000 patients treated in different European risk regions.